96 related articles for article (PubMed ID: 38495872)
1. Psoriasis de novo or exacerbation by PD-1 checkpoint inhibitors.
Wan Z; Huang J; Ou X; Lou S; Wan J; Shen Z
An Bras Dermatol; 2024; 99(3):425-432. PubMed ID: 38388337
[TBL] [Abstract][Full Text] [Related]
2. Anti-TNF alpha-induced paradoxical psoriasis treated with topical roflumilast 0.3.
Hanna E; Benchikh El Fegoun A
JAAD Case Rep; 2024 Jun; 48():115-117. PubMed ID: 38813060
[No Abstract] [Full Text] [Related]
3. Single-cell transcriptomic analysis identifies infiltrating plasmacytoid dendritic cells in psoriasis epidermis.
Luo L; Cheng H; Liu Z; Olszewski P; Pasquali L; Xu N; Enge M; Pivarcsi A; Sonkoly E
Br J Dermatol; 2024 May; ():. PubMed ID: 38776409
[No Abstract] [Full Text] [Related]
4. Human Leukocyte Antigen-Class I Alleles and the Autoreactive T Cell Response in Psoriasis Pathogenesis.
Prinz JC
Front Immunol; 2018; 9():954. PubMed ID: 29760713
[TBL] [Abstract][Full Text] [Related]
5. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
6. Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors.
Morelli M; Carbone ML; Scaglione GL; Scarponi C; Di Francesco V; Pallotta S; De Galitiis F; Rahimi S; Madonna S; Failla CM; Albanesi C
Front Immunol; 2024; 15():1346687. PubMed ID: 38495872
[TBL] [Abstract][Full Text] [Related]
7. Experimental Methods for the Immunological Characterization of Paradoxical Psoriasis Reactions Induced by TNF-α Biologics.
Morelli M; Scarponi C; Madonna S; Albanesi C
Methods Mol Biol; 2021; 2248():155-165. PubMed ID: 33185874
[TBL] [Abstract][Full Text] [Related]
8. Paradoxical psoriasis induced by TNF-α blockade shows immunological features typical of the early phase of psoriasis development.
Fania L; Morelli M; Scarponi C; Mercurio L; Scopelliti F; Cattani C; Scaglione GL; Tonanzi T; Pilla MA; Pagnanelli G; Mazzanti C; Girolomoni G; Cavani A; Madonna S; Albanesi C
J Pathol Clin Res; 2020 Jan; 6(1):55-68. PubMed ID: 31577850
[TBL] [Abstract][Full Text] [Related]
9. ERAP1 Controls the Autoimmune Response against Melanocytes in Psoriasis by Generating the Melanocyte Autoantigen and Regulating Its Amount for HLA-C*06:02 Presentation.
Arakawa A; Reeves E; Vollmer S; Arakawa Y; He M; Galinski A; Stöhr J; Dornmair K; James E; Prinz JC
J Immunol; 2021 Nov; 207(9):2235-2244. PubMed ID: 34580106
[TBL] [Abstract][Full Text] [Related]
10. Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active Psoriasis and localized with keratinocytes, dendritic cells and other leukocytes.
Fuentes-Duculan J; Bonifacio KM; Hawkes JE; Kunjravia N; Cueto I; Li X; Gonzalez J; Garcet S; Krueger JG
Exp Dermatol; 2017 Nov; 26(11):1075-1082. PubMed ID: 28482118
[TBL] [Abstract][Full Text] [Related]
11. Case Report:
Huang JW; Kuo CL; Wang LT; Ma KS; Huang WY; Liu FC; Yang KD; Yang BH
Front Immunol; 2021; 12():752563. PubMed ID: 35003064
[TBL] [Abstract][Full Text] [Related]
12. Dermatologic immune-related adverse events to checkpoint inhibitors in cancer.
Shah NJ; Lacouture ME
J Allergy Clin Immunol; 2023 Feb; 151(2):407-409. PubMed ID: 36463979
[No Abstract] [Full Text] [Related]
13. Role of TL1A in Inflammatory Autoimmune Diseases: A Comprehensive Review.
Xu WD; Li R; Huang AF
Front Immunol; 2022; 13():891328. PubMed ID: 35911746
[TBL] [Abstract][Full Text] [Related]
14. Reduced Interleukin-17-Expressing Cells in Cutaneous Melanoma.
Tosi A; Nardinocchi L; Carbone ML; Capriotti L; Pagani E; Mastroeni S; Fortes C; Scopelliti F; Cattani C; Passarelli F; Rosato A; D'Atri S; Failla CM; Cavani A
Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944746
[TBL] [Abstract][Full Text] [Related]
15. The potential prognostic values of the ADAMTS-like protein family: an integrative pan-cancer analysis.
Zhang X; Yang W; Chen K; Zheng T; Guo Z; Peng Y; Yang Z
Ann Transl Med; 2021 Oct; 9(20):1562. PubMed ID: 34790768
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
